Clinical Trials
16
Trial Phases
4 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (16 trials with phase data)• Click on a phase to view related trials
A Study of YL201 and Ivonescimab (AK112) in Advanced Solid Tumors
- Conditions
- Advanced Solid TumorsNon Small Cell Lung CancerSmall Cell Lung Cancer
- Interventions
- First Posted Date
- 2025-10-06
- Last Posted Date
- 2025-10-06
- Lead Sponsor
- MediLink Therapeutics (Suzhou) Co., Ltd.
- Target Recruit Count
- 260
- Registration Number
- NCT07208773
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
A Study of YL202 in Patients With Advanced Solid Tumors
- Conditions
- Non Small Cell Lung CancerColorectal CancerCervical CancerLocally Advanced or Metastatic Solid Tumors
- Interventions
- First Posted Date
- 2025-10-01
- Last Posted Date
- 2025-10-01
- Lead Sponsor
- MediLink Therapeutics (Suzhou) Co., Ltd.
- Target Recruit Count
- 100
- Registration Number
- NCT07202364
- Locations
- 🇨🇳
Hunan Provincial Tumor Hospital, Changsha, Hunan, China
A Study of YL242 in Subjects With Advanced Solid Tumors
- Conditions
- Advanced Solid Tumor
- Interventions
- Drug: YL242Drug: YL242; PembrolizumabDrug: YL242; 5-FU; LVDrug: YL242; Pembrolizumab; 5-FU
- First Posted Date
- 2025-09-29
- Last Posted Date
- 2025-09-29
- Lead Sponsor
- MediLink Therapeutics (Suzhou) Co., Ltd.
- Target Recruit Count
- 424
- Registration Number
- NCT07197827
- Locations
- 🇺🇸
US-201, New Haven, Connecticut, United States
🇺🇸US-202, Sarasota, Florida, United States
🇺🇸US-204, Boston, Massachusetts, United States
A Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors
- Conditions
- Advanced Solid TumorsBreast CancerNon Small Cell Lung Cancer
- Interventions
- Drug: YL202 for injection; Toripalimab injectionDrug: YL202 for injection; Furmonertinib Mesilate Tablets
- First Posted Date
- 2025-09-12
- Last Posted Date
- 2025-09-12
- Lead Sponsor
- MediLink Therapeutics (Suzhou) Co., Ltd.
- Target Recruit Count
- 414
- Registration Number
- NCT07169994
- Locations
- 🇨🇳
Anhui Provincial Hospital(The First Affiliated Hospital of Ustc), Hefei, Anhui, China
🇨🇳Fujian Cancer Hospital, Fuzhou, Fujian, China
🇨🇳Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors
- First Posted Date
- 2025-03-05
- Last Posted Date
- 2025-07-11
- Lead Sponsor
- MediLink Therapeutics (Suzhou) Co., Ltd.
- Target Recruit Count
- 220
- Registration Number
- NCT06859762
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Columbia University Irving Medical Center, New York, New York, United States
🇺🇸Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio, United States
- Prev
- 1
- 2
- 3
- 4
- Next